Drug
Xarelto (Rivaroxaban, BAY59-7939)
Xarelto (Rivaroxaban, BAY59-7939) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
NCT00839163
completedphase_2
BAY59-7939 Japanese in Atrial Fibrillation (2nd)
NCT00973323
completedphase_2
BAY59-7939 in Atrial Fibrillation Once Daily (OD)
NCT00973245
completedphase_2
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
NCT00395772
Clinical Trials (4)
Showing 4 of 4 trials
NCT00839163Phase 2
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
NCT00973323Phase 2
BAY59-7939 Japanese in Atrial Fibrillation (2nd)
NCT00973245Phase 2
BAY59-7939 in Atrial Fibrillation Once Daily (OD)
NCT00395772Phase 2
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4